Conference Coverage

MRI reliably identifies significant prostate cancer


 

Variation in technique, interpretation

But the quality of care when it comes to the diagnosis of prostate cancer is not equal everywhere, said Gerald Andriole, MD, from the Washington School of Medicine in St. Louis, Missouri.

“When you get an MRI in a center that doesn’t do a lot of prostate cancer testing, you may not have the best software and you may have a radiologist who is not that experienced,” he told Medscape Medical News. Specialized cancer centers of excellence tend to do a great job finding prostate cancer, “but other centers have high significant-miss rates or high overcall rates.”

“The elephant in the room remains the considerable variation in technique and interobserver interpretation of prostate mpMRI,” write Steven Monda, MD, and Marc Dall’Era, MD, both from UC Davis Health in Sacramento, California, in an editorial that accompanies the new PROMIS analysis.

“These problems must be addressed and remedied in each institution before relying on results from PROMIS to drive changes in clinical practice,” they add.

Norris, Andriole, Monda, and Dall’Era have disclosed no relevant financial relationships.

This article first appeared on Medscape.com.

Pages

Recommended Reading

‘A good and peaceful death’: Cancer hospice during the pandemic
MDedge Hematology and Oncology
Can an app guide cancer treatment decisions during the pandemic?
MDedge Hematology and Oncology
American Cancer Society update: ‘It is best not to drink alcohol’
MDedge Hematology and Oncology
‘Hospital at home’ cuts ED visits and costs for cancer patients
MDedge Hematology and Oncology
Personalized cancer vaccine may enhance checkpoint inhibitor activity
MDedge Hematology and Oncology
FDA approves new indications for pembrolizumab
MDedge Hematology and Oncology
FDA approves avelumab as maintenance for urothelial carcinoma
MDedge Hematology and Oncology
Study supports changing classification of renal cell carcinoma
MDedge Hematology and Oncology
AI markers can predict progression, survival in prostate cancer
MDedge Hematology and Oncology
Analysis of early onset cancers suggests need for genetic testing
MDedge Hematology and Oncology